Turnkey toxicological, in vitro, and chemical evaluation platforms accelerating novel botanical actives toward global regulatory approval.
Unlike pure chemical entities, plant extracts contain multi-component phytochemical matrices that necessitate holistic, target-organ toxicology and dynamic bio-analytical tracing.
Determining absolute Median Lethal Dose (LD50), Maximum Tolerated Dose (MTD), and 28-day/90-day repeated dose oral toxicity in rodents and non-rodents under rigorous OECD 407/408 guidelines.
Full suite in vitro and in vivo genotoxicity testing designed to intercept DNA alterations, chromosome aberrations, and carcinogenic triggers prior to human exposure.
Decoupling synergistic herb-drug interactions, CYP450 enzyme induction/inhibition, and hepatorenal clearance burdens triggered by volatile terpenes and polyphenols.
Navigating the stringent global regulatory shifts in the European Union, United States, and Asia-Pacific markets.
Natural botanical medicines and functional ingredients face severe hurdles when entering Western markets. The European Food Safety Authority (EFSA) and the US FDA (NDI / GRAS frameworks) consistently reject herbal dossiers due to incomplete toxicological data sets, trace contaminants, and unstandardized active extracts. As China modernizes Traditional Chinese Medicine (TCM), the industrial demand for GLP-compliant contract research organizations (CROs) has surged dramatically.
MedGence (Yineng Pharma) bridges this structural gap. By uniting native Chinese herbal cultivation bases with modern analytical pharmacology, we generate verifiable safety dossiers that conform to ICH, OECD, and US-FDA standards, unlocking frictionless global commerce.
A plant extract's intrinsic toxicity is frequently conflated with extrinsic toxic contaminants. A rigorous toxicity study must isolate endogenous secondary metabolites from processing artifacts, pesticide residues, and heavy metals.
14+ years of industrial validation serving leading multinational pharmaceutical enterprises and academic hospitals.
End-to-end alignment with international regulatory authorities through our Changsha research hub and partner network.
Structuring the safety dossier with definitive NOAEL (No Observed Adverse Effect Level) derivation, margin of safety (MoS) calculations, and genotoxicity validation for dietary ingredients.
Compiling traditional use justification backed by modern preclinical toxicology to support Well-Established Use (WEU) or Traditional Herbal Medicinal Product (THMP) filings in the EU.
Executing required local safety assessments for Class 1 and Class 2 Innovative Traditional Chinese Medicines and Chinese Blue Hat health food approvals in direct compliance with NMPA decrees.
From single active chemical isolation to complex botanical drug formulations, our toxicological findings serve distinct industrial endpoints.
Substantiating safe consumption levels for novel botanicals, high-potency polyphenols, adaptogenic mushroom fractions, and concentrated herbal teas to eliminate consumer safety liabilities.
Fulfilling rigorous preclinical safety documentation for Investigational New Drug (IND) submissions covering safe starting dose escalation, pharmacokinetics, and toxicokinetics.
Alternative non-animal toxicological validation, including OECD 439 reconstructed human epidermis (RhE) for skin irritation, OECD 432 3T3 NRU phototoxicity, and ocular tolerance assays.
A unified, phase-gated execution plan from botanical raw-material screening to commercial-scale batch supply.
Origin-specific potency evaluation, HPLC/HPTLC fingerprint development, and baseline phytochemical characterization.
Mechanistic cellular toxicity, pathway screening, and in vitro cytotoxicity benchmarks to identify high-efficacy candidate fractions.
Acute LD50, sub-chronic repeated dose studies, mutagenicity batteries, and toxicokinetic NOAEL determination.
Small-group human trial verification for supplements or complete multi-phase clinical research for botanical drug registration.
Direct translation to GMP pilot and commercial manufacturing: liquids, capsules, tablets, granules, and standardized powders.
Providing authoritative toxicity testing, extract standard setting, and contract research for China's premier life-science organizations.
Beijing Tongrentang Group
China Resources Sanjiu
Sunflower Pharmaceutical
Livzon Pharmaceutical
Dihon Pharmaceutical
Golden Throat Holdings
Yangtzi River Pharma
Beihai Gofar Biological
Humanwell Healthcare
SCIMYTH Pharmaceutical
Shandong Hanfang
Luoxin Pharmaceutical
Zhongsheng Pharma
Hunan Brilliance Herbal
Apeloa Pharmaceutical
Hunan Heng Chang
Baotou TCM Co.
Kamp Medicine Co.
Guangxi Santo Pharma
Hunan Kangshou
Jiangxi Juwang Pharma
Beijing Tcmages
Guizhou Ruihe Pharma
Anhui CR Jinchan
Kangmei Pharma
Tianjicaotang Pharma
Jiangxi Kingstone
Shuguang Hospital
Hunan Affiliated TCM
First Hospital Hunan TCM
Second Xiangya Hospital
Second Hospital Hunan TCMEssential guidance for procurement directors, regulatory scientists, and product developers partnering with a Chinese preclinical CRO/CDMO.
Connect with our technical team to schedule safety assays, method establishment, or custom dosage manufacturing.
